Table 1 Normalized values for the expression of MLL-SEPT2 and MLL or SEPT2 in subgroups of hematologic malignacies and normal controls
From: Both SEPT2 and MLL are down-regulated in MLL-SEPT2therapy-related myeloid neoplasia
SEPT2 +MLL-SEPT2 | MLL +MLL-SEPT2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Genetic groups | n | Median (P25–P75) | Fold Change (a) | P-value (a) | P-value (b) | Median (P25–P75) | Fold Change (a) | P-value (a) | P-value (b) |
CBFB-MYH11 | 13 | 3388 (2411–5634) | 9.4 | 0.004 | Ns | 2692 (1698–5099) | 13.4 | 0.025 | ns |
PML-RARA | 12 | 1957 (1055–2904) | 5.4 | 0.004 | 0.001 | 1083 (971–2698) | 5.4 | ns | ns |
RUNX1-RUNX1T1 | 12 | 3187 (2100–3760) | 8.9 | 0.004 | ns | 2107 (1765–3018) | 10.5 | 0.018 | ns |
Normal Karyotype | 11 | 2242 (1604–3424) | 6.2 | 0.005 | 0.010 | 1621 (1012–2895) | 8.1 | ns | ns |
MLL Fusions | 10 | 3069 (2159–4600) | 8.5 | 0.007 | ns | 1292 (708–2050) | 6.4 | ns | 0.023 |
MLL-SEPT2 | 3 | 359 (333–724) | 1.0 | - | 0.007 | 200 (180–1612) | 1.0 | - | 0.028 |
Normal Control | 10 | 4599 (2939–6365) | 12.8 | 0.007 | - | 2494 (1749–3929) | 12.4 | 0.028 | - |